Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

BioMedicine-Taiwan, published by DIGITAL COMMONS BEPRESS, stands as a prominent open-access journal that has been disseminating vital research since 2014. With an ISSN of 2211-8020 and E-ISSN 2211-8039, this journal covers a wide array of disciplines within the biomedical field, reaching researchers and professionals keen on exploring cutting-edge advancements and innovative approaches in biochemistry, genetics, and general medicine. Notably categorized as Q2 in Biochemistry, Genetics and Molecular Biology and Q3 in Medicine for 2023, BioMedicine-Taiwan ranks well in its respective fields, reflecting its commitment to enhancing scholarly communication and knowledge dissemination. Situated in Taiwan, its impact is further highlighted by its Scopus rankings—placing it in the 70th percentile for general medicine and 47th percentile for general biochemistry and molecular biology, showcasing its significance in ongoing biomedical discourse. Researchers, students, and professionals are invited to engage with this invaluable resource to explore the latest findings and developments that shape the future of healthcare and biological sciences.

Bulletin of Russian State Medical University, published by the esteemed PIROGOV RUSSIAN NATL RESEARCH MEDICAL UNIV, serves as a crucial platform for advancing the field of medicine, particularly in the context of Russian healthcare advancements. With an ISSN of 2500-1094 and an E-ISSN of 2542-1204, this journal has emerged as a valuable resource for researchers, professionals, and students alike, enriching the academic landscape since its inception. Although categorized in the Q4 quartile for Medicine (miscellaneous) and currently ranked #385 out of 636 in the Scopus database, its ongoing commitment to disseminating vital research and clinical studies positions it as a respected, though evolving, contributor to the global medical community. Operating without an open-access model, it ensures the dissemination of quality-controlled scientific information while maintaining professional integrity. Spanning the intersecting domains of healthcare practices and medical science, the journal strives to provide insights and promote discussions that address contemporary challenges in the field, making it an essential read for anyone looking to stay at the forefront of medical research and practices in Russia and beyond.

Biomedica is a distinguished journal published by the Instituto Nacional de Salud in Colombia, dedicated to advancing knowledge within the fields of biochemistry, genetics, molecular biology, and general medicine. Since its inception in 1981, this Open Access journal has embodied a commitment to disseminating high-quality research, ensuring free and universal access to its published works. With an impressive Scopus Ranking—273rd out of 636 in Medicine and 148th out of 221 in Biochemistry, Genetics and Molecular Biology—Biomedica holds a Q3 category in both disciplines as of 2023, reflecting its growing impact and relevance in the scientific community. The journal welcomes contributions that further our understanding and lead to advancements in healthcare and biological sciences, serving as a critical resource for researchers, professionals, and students alike. The journal operates within a continuous publication model from 2001 to 2024, enriching the academic landscape with contemporary findings and fostering collaboration within the biomedical field.

Biomedical and Biotechnology Research Journal is a pioneering, peer-reviewed Open Access platform dedicated to the advancement of knowledge in the fields of biomedical science and biotechnology. Published by WOLTERS KLUWER MEDKNOW PUBLICATIONS since 2017, this journal offers a vital resource for researchers, professionals, and students alike, encompassing a wide range of topics from molecular biology to innovative biotechnological applications. With an impact factor reflecting its commitment to quality research, it proudly ranks in the Q3 category for Biotechnology in 2023 and holds significant positions in Scopus ranks, emphasizing its relevance in the medical and biochemistry sectors. The journal is based in India, and with its open access model, it ensures that cutting-edge research is readily available to a global audience, fostering collaboration and innovation in the rapidly evolving world of biomedicine.

Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.